PDSB — PDS Biotechnology Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1472091 ·
Last close
$0.89
Market Cap
$50.03M
52W High
$1.79
52W Low
$0.19
ADV30
7,075,654
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 0 | — | -6,496,734 | -9,750,575 | 8,807,213 | 5,596,254 | 12,386,952 |
| Mar 2026 | 0 | — | -6,521,087 | -7,349,056 | 24,663,026 | 21,660,496 | 20,770,383 |
| Dec 2025 | 0 | — | -6,674,708 | -7,562,919 | 30,494,083 | 26,711,969 | 21,242,250 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,782,788
Investing CF
$0
Financing CF
$-9,494,453
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.71
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-233,706,135
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-27,014,684
Pretax Income TTM
$-33,671,961
Interest Exp TTM
$6,657,277
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -31,543,959 | -34,495,505 | 30,494,083 | 21,242,250 | 9,251,833 | -27,752,012 |
| Dec 2024 | 0 | -36,321,195 | -37,610,384 | 45,358,657 | 26,353,809 | 19,004,848 | -35,030,223 |
| Dec 2023 | 0 | -43,045,234 | -42,942,198 | 59,390,080 | 33,259,133 | 26,130,947 | -33,636,136 |
| Dec 2022 | 0 | -41,672,421 | -40,854,855 | 77,007,923 | 33,005,893 | 44,002,030 | -25,709,706 |
TTM Snapshot
Revenues TTM
$817,987
NetIncome TTM
$-33,671,961
OpCashFlow TTM
—
Assets (Latest)
$8,807,213
Forward EPS
$-0.36
Max Pain — expiry 2027-05-21
max pain strike: $0.50 · spot: $0.78 · call oi: 9,584 · put oi: 1,741
Expected Move to 2027-05-21:
±$0.84
(107.77%) —
implied range
$-0.06 –
$1.63
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ONCY | ONCOLYTICS BIOTECH INC | $50.15M | $0.38 | — |
| APLM | Apollomics Inc. | $49.09M | $16.84 | — |
| HOWL | Werewolf Therapeutics, Inc. | $51.03M | $1.05 | — |
| MIST | Milestone Pharmaceuticals Inc. | $51.44M | $0.41 | — |
| NMAD | NOMAD POWER SOLUTIONS, INC. | $48.30M | $3.00 | — |
News headlines (Yahoo Finance, 1h cache)
PDS Biotechnology: Q3 Earnings Snapshot
2026-11-13 13:10 · Yahoo
PDS Biotech Reports Third Quarter 2026 Financial Results
2026-11-13 13:00 · Yahoo
PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds
2026-11-10 13:00 · Yahoo
PDS Biotechnology (PDSB) Just Flashed Golden Cross Signal: Do You Buy?
2026-11-04 13:55 · Yahoo
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
2026-10-20 12:00 · Yahoo
PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer
2026-10-16 01:02 · Yahoo
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?
2026-10-14 15:00 · Yahoo
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
2026-10-06 12:00 · Yahoo
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncolog
2026-09-22 12:00 · Yahoo
PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny
2026-09-18 21:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.